
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech's fourth-quarter revenues of €1,190 million aligned with consensus estimates, driven by seasonally higher COVID vaccine sales, which are projected to support the company's revenue guidance of €1,700-€2,200 million for fiscal year 2025. The acquisition of Biotheus significantly enhances BioNTech's oncology portfolio, providing the company with a broader range of therapeutic options and reinforcing its position in the oncology market. With a promising and data-rich pipeline scheduled for 2025, including expectations for positive results from ongoing clinical trials in small cell lung cancer, BioNTech is well-positioned for long-term growth and value creation in its core oncology focus.
Bears say
The financial outlook for BioNTech appears negative due to anticipated manufacturing capacity limitations for personalized therapeutics, which may result in delayed revenue generation and adversely affect forecasts. Several risks, including potential negative data for multiple drug candidates, lower-than-expected market adoption, regulatory challenges, and competitive pressures from alternative treatment options, could further hinder the company's financial performance. Additionally, the uncertainty surrounding commercial partnerships and the possibility of adverse events associated with its therapeutic products contribute to a precarious situation for future revenue stability.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares